Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA grants priority review to sNDA for Imbruvica with rituximab in Waldenstrom's macroglobulinemia

June 26, 2018

AbbVie and Calibr establish T-cell therapy collaboration for cancer

June 26, 2018

Pulmatrix reports topline results from phase I/Ib study of Pulmazole

June 26, 2018

Cerenis completes enrollment in TARGET study of CER-001 in esophageal cancer

June 26, 2018

Sophiris reports interim data from phase IIb study of topsalysin for prostate cancer

June 26, 2018

ContraVir doses first subject in first-in-human study of CRV-431

June 26, 2018

Clinuvel files NDA for Scenesse for erythropoietic protoporphyria

June 26, 2018

FDA grants priority review to baloxavir marboxil NDA for influenza

June 26, 2018

FDA approves Epidiolex for seizures associated with LGS and Dravet syndrome

June 26, 2018

Preliminary results of phase II study of entinostat/pembrolizumab in MSS colorectal cancer

June 26, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...